Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention

Michael Lincoff, A.; A. Bittl, John; A. Harrington, Robert; Feit, Frederick; S. Kleiman, Neal; Daniel Jackman, J.; J. Sarembock, Ian; J. Cohen, David; Spriggs, Douglas; Ebrahimi, Ramin; Keren, Gadi; Carr, Jeffrey; A. Cohen, Eric; Betriu, Amadeo; Desmet, Walter; J. Kereiakes, Dean; Rutsch, Wolfgang; G. Wilcox, Robert; J. de Feyter, Pim; Vahanian, Alec; J. Topol, Eric; the REPLACE-2 Investigators, for

doi:10.1001/jama.289.7.853

Public

Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention

Published in JAMA • Feb 19, 2003

Authors:

A. Michael Lincoff

John A. Bittl

Robert A. Harrington

Abstract

CONTEXT: The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during contemporary percutaneous coronary intervention (PCI). OBJECTIVE: To determine the efficacy of bivaliru...

Subject

Medicine

Bivalirudin

Conventional PCI

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!